Introduction
The severity of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) spans a continuum from mild to potentially terminal respiratory failure. Clinicians often have to decide whether a patient is likely to benefit from admission to an intensive care unit (ICU), or whether admission would be futile, and in the UK, NICE guidance suggests that consultants should always be involved in such decisions. 1 However, there is evidence for inconsistency in this decision-making. One reason for this is that a patient's expected chance of survival given access to intubation is usually a factor, 2 and there are difficulties with the necessary prognostication. In an American study, clinicians varied greatly in how they used patients characteristics to formulate prognoses for COPD 3 and similar findings were seen in a process tracing study considering COPD patients for ICU admission in which experienced UK clinicians varied in the number of cues that they considered and the weight that they placed on each cue. 4 In a study of ICU gatekeeping out-of-hours, a group of experienced consultants considered simulated sets of patients with the same characteristics and preferences and subject to the same limits on resources, and made widely varying decisions. 5 Elsewhere we have reported on a comparison of clinicians' prognostic estimates with actual survival in patients with exacerbations of COPD 6 and suggested that in UK practice clinicians' prognoses tended to be pessimistic. This may result in patients being inappropriately denied ICU admission and intubation.
Outcome prediction models can improve the appropriateness and consistency of decision making by suggesting ways of structuring prognostic information. The American SUPPORT study developed an outcome prediction model for patients with acute exacerbations of COPD that was better calibrated than clinicians' mortality estimates. When this model was used to support decision making, the clinicians' mortality estimates became better calibrated. 7 Our aim was to develop a model of this kind to support consultants' ICU gatekeeping decisions in the UK.
Methods
Intensive care units and subjects All ICUs participating in the UK Case Mix Programme, 8 a national comparative audit of critical care units, and three respiratory high dependency units (HDUs) in hospitals with ICUs were invited to take part. Patients were eligible if they were admitted to a participating unit with breathlessness, respiratory failure or change in mental status due to an exacerbation of obstructive airways disease. Recruitment was on admission to the unit. Differentiating COPD from asthma can be difficult in the acute setting; 9 objective information may not be available and a significant proportion of patients with COPD actually think that they have asthma. The study design accommodated this uncertainty by allowing clinicians to make a clinical categorization of the airways obstruction as either pure COPD, pure asthma or a mixture of asthma and COPD. Data were collected for admissions between March 2002 and September 2003 inclusive. More details are given elsewhere. 10 The study received Multi-centre Research Ethics Committee approval.
Data collected
A literature search provided a list of variables previously shown to be associated with survival in patients with acute exacerbations of COPD. Data were collected on a subset of these variables that were likely to be available prior to ICU admission. In some cases more than one indicator of the same underlying variable was included; for example body mass index (BMI), mid-arm circumference (MAC) and body weight assessment on a Lickert scale were all collected as indicators of under weight. Information on the patient's functional 12, 13 and health state prior to ICU admission was obtained from the clinical record, the patient, relatives or the clinical team. For a set of acute physiological variables, information was collected on the most extreme values in the 24 h preceding ICU admission. A description of coexistent medical problems was collected using the Charlson comorbidity score.
14 The admitting doctor in each case was asked to estimate the patient's probability of survival for 180 days after admission. These data were faxed to the study coordinating centre within 24 h of ICU admission so that problems with missing or suspect data could be resolved whilst the patient was still in the unit. When patients were discharged from the unit, or died while in it, information was collected on the respiratory support they had actually received.
The primary outcome measure was survival to 180 days after the admission, which led to recruitment to the study. Survival was determined initially from the general practitioner and confirmed by the Office of National Statistics.
We judged that a model with about 20 continuous variables or categories would be simple enough for clinical use. The target sample size was determined by the need to have a minimum of 10 outcome events per parameter in the final model, 15 which implied a cohort with at least 200 deaths by 180 days.
Model building and evaluation
To reduce the number of model parameters to be estimated from the study data, a COPD-specific acute physiology score (CAPS) was developed using a different and much larger dataset. This covered 8527 patients in the Case Mix Programme database aged >45 years admitted to intensive care with a diagnosis of obstructive lung disease. The data were from the 24 h following admission. The CAPS score had a range from 1 to 100. It was simpler to calculate and was a better predictor of outcome in the UK population than the acute physiology score from APACHE III used in the SUPPORT model. 16 The prognostic model was developed using data from all 832 patients recruited to the study. Variables were dropped if the proportion of cases with missing data was >5%, 17 if they had proved difficult to collect during the study, or if they were judged likely to introduce selection bias. Where more than one variable measuring a single domain had been successfully collected the criteria for choice were simplicity of measurement and objectivity.
The resulting shortlist of variables was used in a logistic regression model for predicting 180-day mortality. Variables were dropped from this model if they had a very weak association with outcome (backward stepwise variable selection with a P > 0.2) and their place on the shortlist was supported only by previous studies of low power and quality. The effects of continuous variables were inspected for non-linearity using Lowess and partial residual plots, 18 and tested using fractional polynomials. 19 The model with the final set of selected variables was converted to a prognostic score with a unit change in the CAPS score having a weight of one. The model's capacity to discriminate was evaluated using the area under the ROC curve (c) and the P-value for the null hypothesis of no improvement in c over the doctors' estimates. For calibration, Hosmer-Lemeshow chi-square with 10 groups and the calibration slope were used. The expected effects on performance of over-fitting or 'optimism' were assessed by a regular 1000-iteration bootstrap procedure. 20 For each bootstrap sample a new model was estimated (new coefficients, same variables) and the performance of the new model in the sample data was compared with its performance in the original data. The distributions of differences in performance in the 1000 bootstrap samples were used to adjust the performance measures for overfitting. Also for each bootstrap sample, the observed survival rate was calculated for each decile of predicted risk. The 2.5th and 97.5th percentiles of the differences between observed and predicted survival in the 1000 bootstrap samples provided the confidence intervals for the calibration plot. Mean differences in calibration slope and intercept were used to adjust the original model for overfitting when estimating risk. 21 
Role of the funding source
The funder had no role in the design, analysis, interpretation or reporting of this research.
Results

Participation of units
Of the 174 eligible units in the Case Mix Programme at the time, 92 (53%) agreed to take part. Overall, the participating and non-participating units were similar in terms of type, size, affiliation, mean numbers of admissions of any kind per unit during the study period and the percentages of admissions eligible for the study. Among patients eligible for the study, the COPD acute physiology scores and ICU mortality rates were also similar for participating and non-participating units. 10 
Recruitment of patients and generalizability
Eight hundred and thirty-two patients were recruited. In another analysis of the Case Mix Programme database, the 648 patients in the database and also recruited to the study were compared with the 996 patients in the database, admitted to participating ICUs and satisfying the inclusion criteria, but not recruited to the study. There was no evidence for differences in terms of age, CAPS or ICU mortality. 10 
Ventilation and outcome
Of the 832 patients recruited, 450 (54%) were intubated and 517 (62%) were alive 180 days after ICU admission.
Predictors of survival
Reasons for dropping 13 variables from the literature-based shortlist are given in Table 1 . If the composite CAP score derived from the CMP database is counted as one variable, this left nine in the final model. Table 2 shows their distributions and the corresponding mortality rates, with univariate and multivariate odds ratios. Continuous variables have been categorized for the purposes of this table only.
There were missing data on mean arm circumference (MAC) in 13 cases (2.6%), but the data on bodyweight Likert score were complete. Missing MAC scores were imputed from the mean MAC scores of patients with the same Likert score. Data were missing for the Glasgow Coma Score in three cases (0.4%), and these were all assumed to have the maximum score of 15.
There was no evidence to suggest that the effects of acute physiology or Glasgow coma scores were other than linear. The 'length of stay in hospital before critical care admission' variable was treated as linear in effect up to a maximum of 6 days. Fractional polynomial analysis suggested that the MAC effect was non-linear, but the effect of a transformed version ('centimetres less than 30', e.g. a MAC of 25 cm scoring 5 and MACs of 30 or more scoring zero) was linear. The effect of a transformed age variable ('years of age above 70', e.g. age 75 scoring 5 and age <70 scoring 0) was also linear.
Interactions for age, sex and diagnosis with the other variables in the model were examined. Three significant interactions were found but they did not add materially to prognostic performance and were left out of the final model to keep it simple to use.
The formula for the prognostic score is: Ã cm mid-arm circumference less than 30 + 1.6 Ã (15-Glasgow coma score, i.e. difference between best possible and actual) + COPD acute physiology score Figure 2 shows a scoring sheet for the prognostic index, and Figure 3 shows a scoring sheet for the CAP score. The risk is calculated from: 
Model performance
The calibration curve for the final model is shown in Figure 4 , and other indicators of its performance in Table 3 ; the area under the receiver operating curve (c) was 76.1% unadjusted and 74.7% after bootstrapping. For comparison, in a benchmark model with age over 70 years and sex as the only predictors, c was 63.3% after bootstrapping. For the doctors' estimates, c was 71.2%. As can be seen from Figure 4 , the final model was much better calibrated than the doctors, and the bootstrapped P in Table 3 shows that it was slightly but significantly more discriminating (P = 0.03).
Model variants
A number of variants were tried with the objective of making the model easier to use, e.g. by simplifying the acute physiology and Glasgow scores, and categorizing age, length of stay and MAC. Variants were found which performed almost as well as the final model but on balance the improvements in usability were small, and subject to concerns about overfitting.
Discussion
In another analysis of data from the CAOS study, we report that 73% of the survivors responding to a questionnaire considered their quality of life to be the same as or better than it had been in the stable period before they were admitted, and 96% would choose similar treatment again. 10 This suggests that, for COPD patients, survival to 180 days after ICU admission is a worthwhile objective. A model that predicts 180-day survival in patients with severe acute exacerbations of chronic obstructive pulmonary disease admitted to ICU has been developed using data available prior to ICU admission. The model has fair discrimination, better than the clinicians overall. However, its main advantage is that it is well calibrated, free of the clinicians' clear tendency to pessimism during decisions to admit these patients to ICU. 6 How valid is this model? In pursuit of internal validity (which requires the model to perform well on a population sampled from) we: ensured a high rate of follow-up; adhered to guidelines in terms of variable selection, which was based primarily on a priori considerations rather than driven by our own data; avoided categorization of continuous variables; and used bootstrapping to adjust the measures of discrimination and calibration for 'optimism'.
While bootstrapping has its critics, it is increasingly recognized as efficient approach to questions of internal validity. 21 The assumption is that the data at hand can be treated as a random sample from a larger population. In general a model with coefficients estimated using the data at hand will fit these data better than another random sample from the same population. Ignoring this 'over-fitting' leads to 'optimism' about how well the model would perform in the larger population. One approach has been to calibrate the model on a selected part of Multiply each 'new' value by its weight and put the answer in the 'Score' column.
For Acute Physiology Score in T3 there is no weight; just write the APS in the 'Score' column 1 . Cannot get out of house unassisted or gets out of the house rarely; able to perform self-care but unable to do heavy chores such as house cleaning, cannot live alone; may be institutionalized 2. Able to live on their own and get out of the house to do basic necessities but severely limited in exercise ability selecting the required number of random patients from the data at hand. New sets of model coefficients are estimated for each bootstrap sample, and tested in the original sample. This provides a distribution of estimates of the contribution of over-fitting to the original model's performance. It also provides a basis for 'shrinking' the coefficients in original model so as to provide a 'corrected' model that performs a little less well than the original one in the data at hand, but should perform about as well in any other sample from the larger population. This does not address the question of external validity, which requires the population sampled from to be the same as the population of interest. This is always more difficult to assess, even in the best randomized trials. However there was no evidence from the Case Mix Programme database of biased selection, either in the characteristics of the units participating or in the eligible patients enrolled. Testing the model on data from other studies would have been more convincing, but there could be no independent UK study in the same period of comparable size because so many units were recruited to this one. Testing the model on more recent data would certainly be of interest because of the increasing use of non-invasive ventilation.
The CAOS study included patients who had no respiratory support, patients who received NIV, and patients who were intubated. Information on the type and success of ventilation would have improved the performance of the model. However the aim was to inform decisions about admission to ITU, and so the relevant data would have been the nature of any ventilation prior to ICU admission, and how successful it had been. Our pilot work showed that these data were seldom available at the time the decision had to be made.
Ideally a model for supporting decisions about admission to intensive care would be based on a study in which all patients who might ever be considered for intensive care were provided with it. The American SUPPORT study 7 came reasonably close to this. It aimed to recruit all patients in the participating hospitals with exacerbation of COPD and a PaCO 2 of 50 mmHg (6.6 kPa) or more, and the numbers of patients who could have benefited from intensive care but were denied it will have been relatively small. The variables in the SUPPORT prognostic score are age, acute physiology from the third day of the hospital stay (using the APACHE III system), albumin, PaO 2 /FiO 2 ratio, activities of daily living, BMI, congestive heart failure, cor pulmonale and number of comorbidities. The area under their ROC curve, calibrated on the first 600 and tested on the last 416 patients recruited, was 71.0%.
In our study, we only recruited patients once they have been admitted to ICU or HDU. Clearly if the selection of our cohort of patients from all candidates for ICU/HDU was biased by some positive prognostic factor that is (i) not in the model and (ii) independent of the factors that are in it, then applying the model to all candidates would tend to give optimistic prognoses. But there is no evidence in the literature for the existence of any such factor; on the contrary, detailed process-tracing studies of clinical decision making suggest marked between-doctor variation in the use of prognostic cues. 2 Moreover candidates in the UK will be more likely than in the US to have been denied intensive care even though they would have benefited from it. Basing a prognostic model on all candidates would thus give pessimistic prognoses. 22 Also the American study involved teams of data collectors for every hospital, which was beyond our means. Our strategy was to recruit units with a wide range of admission severity thresholds and we were successful in this.
Decisions about admission to ICU have to be made in the light of the information available at the time, and for some patients diagnosis at the time will be provisional or uncertain. For example classification of smokers with obstructive airways disease into pure COPD or pure asthma can be difficult even after outpatient assessment and with full pulmonary function support. 9 On the other hand provisional diagnoses may have prognostic value, and we found that 'pure asthma' did have a much better prognosis, and 'COPD AE asthma' a slightly better prognosis, than the 'pure COPD' group.
It is unclear why males carry a greater risk than females. It may be that this is through a link to otherwise unmeasured comorbidity. Collecting comorbidity data effectively in the acute setting can be difficult and the Charlson co-morbidity score used in this study did not predict mortality well.
How might the CAOS model contribute to patient care? There are two main uses for prognostic scores: to adjust for case mix in audit and non-randomized studies, and to support clinical decision making. With regard to case mix adjustment for COPD patients, we have not made a direct comparison with APACHE II and III, but APACHE scores are generic rather than disease specific and require more data. The CAPS score used in CAOS has been shown to be more discriminating for COPD patients than the acute physiology scores of APACHE II and III. 16 The SUPPORT model has not been calibrated for the UK and was less discriminating to start with. Also it requires data that are collected up to 72 h after ICU admission whereas ideally a case mix adjustment model should not use variables that may have been affected by the treatment being evaluated. Thus the CAOS score should be a better basis for UK case-mix adjustment than APACHE or SUPPORT.
The use of models to support clinical decision making is more controversial. One concern is that models provide prognostic estimates for groups, not individuals. Given 100 patients with a score of x, a model will suggest that on average y will survive. In reality there will be substantial variation in risk between patients with the same prognostic score, and the extent of this variation is unclear. (The expected error in the risk associated with given prognostic score may be indicated by a confidence interval, but this would be a reflection of the power of the calibration study to estimate group risk, not the limits of individual risk.) Some clinicians may feel that group-level risks are an unsuitable basis for decisions about individuals. But prognoses based on clinical judgment alone are also inherently uncertain. Moreover they depend on the clinician as well as the patient, and are vulnerable to unconscious bias. If clinicians feel that the uncertainties inherent in a prognosis are unacceptable the recommended approach would be to continue active treatment until things become clearer. 23 Thus the prime motivations for this study were the variability and pessimism of clinical estimates of survival for COPD patients, and the implications for decisions about admission to ICU. 6 How then might this study help improve decision making? Simulation studies have suggested that clinicians' prognoses for COPD patients are both variable and pessimistic. Studies of actual decision making in the USA 7 and in the UK 6 have found pessimistic prognoses for COPD in clinical practice. In the SUPPORT study, it was found that clinicians were able to make the most accurate prognoses when they were formulated alongside information from the SUPPORT model. This should not be surprising. The human mind finds it very difficult to deal with more than a small number of pieces of information even if they are simply being added up, whereas prognostic factors may well interact in ways that are not directly additive. 24 When de Dombal introduced a decision aid into the diagnostic process for abdominal pain, part of the improvement in decision making was attributed to helping clinicians attend to all relevant cues and become 'better calibrated'. 25 The prediction model we have developed is based on 180-day outcomes that many decision makers are unaware of, and on more patients with acute severe exacerbations of COPD than most will be able to bring readily to mind. We believe that it could help clinicians with a very challenging task if they use it together with their judgment to strengthen their cue selection and synthesis, and their calibration.
As well as pessimistic and inconsistent prognoses, the consultants in the Heart of England Network reported widely varying thresholds for admission. One question that remains is what the appropriate prognostic threshold should be for ICU admission for patients with exacerbations of chronic disease. For care to be both efficient and equitable, both accurate prognosis and a broad consensus about the indications for treatment are required.
